Open AccessThe role of lamivudine in the treatment of HBe antigen negative liver cirrhosis
Author(s) -
Jasmina Simonović-Babić,
Dragan Delić,
Neda Švirtlih,
Sladjana Pavić,
Nataša Popović,
Jasmina Poluga
Publication year - 2006
Publication title -
medicinski pregled
Language(s) - English
Resource type - Journals
eISSN - 1820-7383
pISSN - 0025-8105
DOI - 10.2298/mpns0608317s
Subject(s) - medicine , lamivudine , cirrhosis , gastroenterology , hbeag , ascites , liver function , hbsag , hepatitis b , liver disease , decompensation , hepatitis b virus , interferon , hepatorenal syndrome , immunology , virus
Lamivudine is effective in suppressing hepatitis B virus replication and hepatic necroinflammatory activity. Patients with HBV-related chronic liver disease often present with hepatic decompensation and are not eligible for interferon therapy. The effectiveness of antiviral therapy in preventing disease progression in patients with hepatitis B cirrhosis is unknown. The aim of this study was to evaluate the effectiveness of lamivudine treatment in patients with cirrhosis due to chronic hepatitis B.